Last reviewed · How we verify
TQH2722 injection 600mg-300mg
TQH2722 injection 600mg-300mg is a Small molecule drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. It is currently in Phase 2 development.
At a glance
| Generic name | TQH2722 injection 600mg-300mg |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TQH2722 injection 600mg-300mg CI brief — competitive landscape report
- TQH2722 injection 600mg-300mg updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI
Frequently asked questions about TQH2722 injection 600mg-300mg
What is TQH2722 injection 600mg-300mg?
TQH2722 injection 600mg-300mg is a Small molecule drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..
Who makes TQH2722 injection 600mg-300mg?
TQH2722 injection 600mg-300mg is developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (see full Chia Tai Tianqing Pharmaceutical Group Co., Ltd. pipeline at /company/chia-tai-tianqing-pharmaceutical-group-co-ltd).
What development phase is TQH2722 injection 600mg-300mg in?
TQH2722 injection 600mg-300mg is in Phase 2.